LON:PRTC PureTech Health (PRTC) Share Price, News & Analysis GBX 116.40 0.00 (0.00%) As of 12:20 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesBuy This Stock About PureTech Health Stock (LON:PRTC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PureTech Health alerts:Sign Up Key Stats Today's Range 115▼ 118.2050-Day Range 115.20▼ 146.6052-Week Range 100.40▼ 178Volume576,456 shsAverage Volume681,593 shsMarket Capitalization£280.89 millionP/E Ratio684.71Dividend YieldN/APrice TargetGBX 455Consensus RatingBuy Company Overview PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia. In addition, the company is developing drug delivery platform for oral administration of proteins, peptides, and other difficult-to-deliver payloads; products to generate new human hair follicles and hair; drug delivery platform for drugs that treat inflammation and associated disorders; platform to address immunosenescence; novel targeted immunotherapies for cancer; monoclonal antibodies for immuno-suppressive gamma delta T cells in pancreatic and colorectal cancers, and other solid tumors; novel approaches to enhance delivery and distribution of therapeutics; and digital health technologies, as well as engages in enhancing health through food through the creation of nutrition technology. Further, it is developing a platform and products that take in physiological data from sensors and correlates that data with musical data components; voice-based tools for passive assessment and tracking of patient health; commensal organism-based products for enhancing human health; and technology platform to identify experts in healthcare and other research-based disciplines, as well as engages in identifying healthcare expert networks and reviewing their conversations and content on social media. The company was incorporated in 2015 and is based in Boston, Massachusetts. Read More PureTech Health Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScorePRTC MarketRank™: PureTech Health scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPureTech Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePureTech Health has received no research coverage in the past 90 days.Read more about PureTech Health's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of PureTech Health is 684.71, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 262.22.Price to Earnings Ratio vs. SectorThe P/E ratio of PureTech Health is 684.71, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 59.11.Price to Book Value per Share RatioPureTech Health has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for PRTC. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPureTech Health does not currently pay a dividend.Dividend GrowthPureTech Health does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for PRTC. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for PureTech Health this week, compared to 1 article on an average week. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, PureTech Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought £1,677.39 in company stock and sold GBX 0 in company stock.Percentage Held by Insiders13.13% of the stock of PureTech Health is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions53.06% of the stock of PureTech Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about PureTech Health's insider trading history. Receive PRTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PureTech Health and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRTC Stock News HeadlinesPureTech Health Advances Deupirfenidone in IPF TreatmentAugust 21, 2025 | msn.comPureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New ...August 21, 2025 | sg.finance.yahoo.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.September 4 at 2:00 AM | American Alternative (Ad)PureTech Health to Announce Half-Yearly Financial ResultsAugust 18, 2025 | msn.comPureTech says Vedanta ulcerative colitis study missed endpointAugust 14, 2025 | msn.comPureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory DiseasesAugust 12, 2025 | finance.yahoo.comPureTech Health Launches Celea Therapeutics to Revolutionize Respiratory Disease TreatmentAugust 12, 2025 | msn.comWith 71% ownership of the shares, PureTech Health plc (LON:PRTC) is heavily dominated by institutional ownersJuly 27, 2025 | finance.yahoo.comSee More Headlines PRTC Stock Analysis - Frequently Asked Questions How have PRTC shares performed this year? PureTech Health's stock was trading at GBX 150.20 at the start of the year. Since then, PRTC shares have decreased by 22.5% and is now trading at GBX 116.40. How do I buy shares of PureTech Health? Shares of PRTC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of PureTech Health own? Based on aggregate information from My MarketBeat watchlists, some other companies that PureTech Health investors own include IQE (IQE), Royal Dutch Shell (RDSB), BP (BP), GSK (GSK), Hummingbird Resources (HUM), Plug Power (PLUG) and AstraZeneca (AZN). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:PRTC CIKN/A Webpuretechhealth.com Phone+1-617-4822333FaxN/AEmployees300Year FoundedN/APrice Target and Rating Average Price Target for PureTech HealthGBX 455 High Price TargetGBX 455 Low Price TargetGBX 455 Potential Upside/Downside+290.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)GBX 0.17 Trailing P/E Ratio684.71 Forward P/E RatioN/A P/E GrowthN/ANet Income-£91.86 million Net Margins-17,620.94% Pretax MarginN/A Return on Equity-21.15% Return on Assets-13.39% Debt Debt-to-Equity Ratio45.82 Current Ratio3.68 Quick Ratio2.51 Sales & Book Value Annual Sales£6.17 million Price / Sales45.55 Cash FlowGBX 54.35 per share Price / Cash Flow2.14 Book ValueGBX 113.55 per share Price / Book1.03Miscellaneous Outstanding Shares241,316,000Free FloatN/AMarket Cap£280.89 million OptionableNot Optionable Beta1.02 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (LON:PRTC) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PureTech Health plc Please log in to your account or sign up in order to add this asset to your watchlist. Share PureTech Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.